Renal Cell Carcinoma | Clinical

HIF-2α Inhibitors and Other Targeted Therapies Appear Promising in VHL-Associated RCC

January 07, 2021

The role of immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors appear encouraging for the treatment of patients with kidney cancer following recent research on targeting von Hippel-Lindau disease-associated renal cell carcinoma.

Pazopanib Effective and Safe in Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma

January 06, 2021

Pazopanib, a tyrosine kinase inhibitor, is active and well-tolerated in patients with poor-risk metastatic clear cell renal cell carcinoma with no new safety signal observed, according to results from the phase 4 FLIPPER clinical trial.

Telaglenastat/Cabozantinib Does Not Prolong PFS in Advanced or Metastatic RCC

January 04, 2021

Treatment with telaglenastat in combination with cabozantinib did not improve progression-free survival in patients with advanced or metastatic renal cell carcinoma when compared with cabozantinib alone, missing the primary end point of the phase 2 CANTANA clinical trial.

Novel HIF-2α Inhibitor Achieved Durable Responses in VHL-Associated RCC

December 05, 2020

Treatment with MK-6482, an investigational HIF2α inhibitor, demonstrated durable efficacy as treatment of patients with Von Hippel-Lindau-associated renal cell carcinoma and non-renal lesions, according to phase 2 data presented during the 21st Annual Meeting of the Society of Urologic Oncology.

HIF-2α Inhibition Warranted for VHL-Associated Clear Cell Renal Cell Carcinoma

December 03, 2020

The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau disease-associated clear cell renal cell carcinoma and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology.

Lenvatinib Plus Everolimus Induces Responses in Rare RCC Population

November 18, 2020

In an interview with Targeted Oncology, Thomas E. Hutson, DO, PharmD, discussed the difficult-to-treat nccRCC patient population and the promise of lenvatinib plus everolimus, as well as other combination regimens.